Form 4: Provectus Biopharmaceuticals Executive Converts Preferred Stock

Dominic Rodrigues, President of Provectus Biopharmaceuticals, converted Series D Convertible Preferred Stock into Series D-1 Convertible Preferred Stock on June 25, 2024.

Summary

• On June 25, 2024, Dominic Rodrigues, President of Provectus Biopharmaceuticals, converted 11,416,242 shares of Series D Convertible Preferred Stock into 1,141,626 shares of Series D-1 Convertible Preferred Stock.
• This conversion was executed pursuant to a Conversion Agreement dated June 21, 2024, between Rodrigues and the Issuer.
• Each share of Series D Convertible Preferred Stock is convertible into one share of Common Stock.
• Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of Common Stock.
• Both Series D and Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Sentiment

Score: 5

Explanation: The document is a standard SEC Form 4 filing, indicating a routine transaction. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The Series D and D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.

Industry Context

This filing is a routine disclosure related to executive stock ownership and conversions, common in publicly traded companies.

Stakeholder Impact

• The conversion of preferred stock to common stock could potentially impact shareholders by diluting the value of existing shares, depending on the number of shares ultimately converted.

Key Dates